Protocol of CLOuD of published in the BMJ
A research protocol for a randomised parallel study assessing the effect of closed-loop insulin delivery from onset of type 1 diabetes in youth on residual beta-cell function compared to standard insulin therapy has been published in the British Medical Journal, on behalf of the CLOuD Consortium.
Professor of Metabolic Technology, University of Cambridge
The CLOuD study builds on recent technological advances of closed-loop insulin delivery (artificial pancreas). The purpose of this study is to test the impact of continued intensive metabolic control using closed-loop insulin delivery after diagnosis on preservation of C-peptide residual secretion.
The primary objective is to evaluate the effect of continued intensive metabolic control using closed-loop insulin delivery after diagnosis on preservation of C-peptide residual secretion by comparing the area under the stimulated C-peptide curve (AUC) of a mixed meal glucose tolerance test conducted at the 12-month visit in participants receiving closed-loop insulin delivery with those receiving standard therapy, i.e. multiple daily injections applying basal-bolus regimen.
Published April 22, 2020
Latest from CCTU
Research sets global standard for Crohn’s treatment
Trial results published by Cambridge researchers earlier this year and involving patients at Addenbrooke’s Hospital are helping to set new global standards…
Team praised for “game-changing” heart trial
A senior Addenbrooke’s early phase trials researcher has praised patients, staff and sponsors who backed a landmark trial which could be a “game changer” in…
Improving outcomes for Crohn's patients
Treating newly-diagnosed patients with advanced therapy leads to dramatic improvements in outcomes.
